metformin has been researched along with Psoriasis in 12 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Single centre, parallel group, randomized, study of metformin, pioglitazone and placebo in psoriasis patients with MS." | 9.22 | Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). ( Bhansali, A; Singh, S, 2016) |
| "The safety of metformin usage by diabetic psoriasis patients is unclear." | 7.91 | Safety of Metformin in Psoriasis Patients With Diabetes Mellitus: A 17-Year Population-Based Real-World Cohort Study. ( Chen, TH; Chi, CC; Chiu, WT; Hsu, CY; Lin, YS; Su, YJ, 2019) |
| "Bexarotene (BEX) is a specific RXR agonist and an antineoplastic agent indicated by the FDA for cutaneous T-cell lymphoma (CTLA)." | 5.91 | Design, synthesis and characterization of a novel multicomponent salt of bexarotene with metformin and application in ameliorating psoriasis with T2DM. ( An, Q; Du, G; Hao, Y; Li, W; Lu, Y; Ren, L; Wang, J; Yang, D; Yang, H; Yang, Y; Yu, M; Zhang, S; Zhang, Y, 2023) |
| "Single centre, parallel group, randomized, study of metformin, pioglitazone and placebo in psoriasis patients with MS." | 5.22 | Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). ( Bhansali, A; Singh, S, 2016) |
| "The current evidence demonstrates therapeutic efficacy of pioglitazone, which may be a treatment option in patients with psoriasis and diabetes mellitus." | 5.12 | Effects of antidiabetic drugs on psoriasis: A meta-analysis. ( Chi, CC; Lee, CY; Liu, CY; Tien O'Donnell, F; Tung, TH; Wang, SH, 2021) |
| "The safety of metformin usage by diabetic psoriasis patients is unclear." | 3.91 | Safety of Metformin in Psoriasis Patients With Diabetes Mellitus: A 17-Year Population-Based Real-World Cohort Study. ( Chen, TH; Chi, CC; Chiu, WT; Hsu, CY; Lin, YS; Su, YJ, 2019) |
| "After treatment of psoriasis patients with a traditional anti-psoriatic drug in combination with metformin and peroxisome proliferator-activated receptor gamma (PPARɤ) agonist (pioglitazone), the CD4+ T cells, IL-2, CRP, CP, ALT and AST levels were statistically significantly decreased compared to psoriasis patients without treatment." | 3.85 | Mechanism of action and effect of immune-modulating agents in the treatment of psoriasis. ( Ahmed, AS; Al-Najjar, AH; El-Gharabawy, RM, 2017) |
| "Bexarotene (BEX) is a specific RXR agonist and an antineoplastic agent indicated by the FDA for cutaneous T-cell lymphoma (CTLA)." | 1.91 | Design, synthesis and characterization of a novel multicomponent salt of bexarotene with metformin and application in ameliorating psoriasis with T2DM. ( An, Q; Du, G; Hao, Y; Li, W; Lu, Y; Ren, L; Wang, J; Yang, D; Yang, H; Yang, Y; Yu, M; Zhang, S; Zhang, Y, 2023) |
| "Psoriasis is an autoimmune inflammatory skin disorder consists of hyperkeratosis, abnormal keratinization, acanthosis, and infiltration of inflammatory cells in the dermis." | 1.62 | Co-encapsulation of metformin and ginger into the liposomes: ( Jenabikordi, K; Rezaie, A; Zadeh, BSM, 2021) |
| "Psoriasis is a prevalent, chronic inflammatory skin disease that arises from rapid and excessive growth of keratinocytes induced by abnormal inflammatory responses." | 1.51 | Metformin inhibits pro-inflammatory responses via targeting nuclear factor-κB in HaCaT cells. ( Ba, W; Chi, S; Li, C; Wang, R; Wang, Y; Xu, Y; Yang, J; Yin, G, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jenabikordi, K | 1 |
| Zadeh, BSM | 1 |
| Rezaie, A | 1 |
| Yang, Y | 1 |
| Yu, M | 1 |
| Ren, L | 1 |
| An, Q | 1 |
| Li, W | 1 |
| Yang, H | 1 |
| Zhang, Y | 1 |
| Zhang, S | 1 |
| Hao, Y | 1 |
| Du, G | 1 |
| Yang, D | 1 |
| Lu, Y | 1 |
| Wang, J | 1 |
| Chi, CC | 2 |
| Lee, CY | 1 |
| Liu, CY | 1 |
| Wang, SH | 1 |
| Tien O'Donnell, F | 1 |
| Tung, TH | 1 |
| Chang, JE | 1 |
| Choi, MS | 1 |
| Ba, W | 1 |
| Xu, Y | 1 |
| Yin, G | 1 |
| Yang, J | 1 |
| Wang, R | 1 |
| Chi, S | 1 |
| Wang, Y | 1 |
| Li, C | 1 |
| Su, YJ | 1 |
| Chen, TH | 1 |
| Hsu, CY | 1 |
| Chiu, WT | 1 |
| Lin, YS | 1 |
| Kim, SC | 1 |
| Schneeweiss, S | 1 |
| Glynn, RJ | 1 |
| Doherty, M | 1 |
| Goldfine, AB | 1 |
| Solomon, DH | 1 |
| Singh, S | 1 |
| Bhansali, A | 1 |
| El-Gharabawy, RM | 1 |
| Ahmed, AS | 1 |
| Al-Najjar, AH | 1 |
| Koca, R | 1 |
| Altinyazar, HC | 1 |
| Yenidünya, S | 1 |
| Tekin, NS | 1 |
| Brauchli, YB | 1 |
| Jick, SS | 1 |
| Curtin, F | 1 |
| Meier, CR | 1 |
| Moore, AF | 1 |
| Soper, T | 1 |
| Jones, N | 1 |
| Grevelink, J | 1 |
| Abourizk, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism: A Double-Blind, Randomized, Placebo-Controlled Study[NCT03629639] | Phase 4 | 80 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for metformin and Psoriasis
| Article | Year |
|---|---|
Effects of antidiabetic drugs on psoriasis: A meta-analysis.
Topics: Humans; Hypoglycemic Agents; Liraglutide; Metformin; Pioglitazone; Psoriasis; Rosiglitazone; Treatme | 2021 |
A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders.
Topics: Acanthosis Nigricans; Acne Vulgaris; Dermatitis, Allergic Contact; Hidradenitis Suppurativa; Humans; | 2020 |
1 trial available for metformin and Psoriasis
| Article | Year |
|---|---|
Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort).
Topics: Adult; Aged; Analysis of Variance; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; M | 2016 |
9 other studies available for metformin and Psoriasis
| Article | Year |
|---|---|
Co-encapsulation of metformin and ginger into the liposomes:
Topics: Administration, Cutaneous; Animals; Liposomes; Metformin; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2021 |
Design, synthesis and characterization of a novel multicomponent salt of bexarotene with metformin and application in ameliorating psoriasis with T2DM.
Topics: Animals; Bexarotene; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Imiquimod; Metformin; Mic | 2023 |
Metformin inhibits pro-inflammatory responses via targeting nuclear factor-κB in HaCaT cells.
Topics: Cells, Cultured; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Inflammation; Metfor | 2019 |
Safety of Metformin in Psoriasis Patients With Diabetes Mellitus: A 17-Year Population-Based Real-World Cohort Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; | 2019 |
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2015 |
Mechanism of action and effect of immune-modulating agents in the treatment of psoriasis.
Topics: Adrenal Cortex Hormones; Adult; Cholecalciferol; Coal Tar; Drug Therapy, Combination; Female; Humans | 2017 |
Psoriasiform drug eruption associated with metformin hydrochloride: a case report.
Topics: Adolescent; Biopsy; Drug Eruptions; Female; Humans; Hypoglycemic Agents; Metformin; Psoriasis | 2003 |
Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study.
Topics: Administration, Oral; Adult; Aged; Case-Control Studies; Databases, Factual; Drug Administration Sch | 2008 |
Psoriatic exacerbation associated with insulin therapy.
Topics: Aged; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Insulin; Insulin | 2008 |